The 30 references in paper Yu. Gorinova V., S. Krasovskiy A., O. Simonova I., E. Amelina L., Ю. Горинова В., С. Красовский А., О. Симонова И., Е. Амелина Л. (2017) “Ингаляционный маннитол – новый муколитический препарат для лечения муковисцидоза // Inhaled mannitol as a new mucolytic for treatment of cystic fibrosis” / spz:neicon:pulmonology:y:2016:i:6:p:760-765

1
Капранов Н.И., Каширская Н.Ю. ред., Муковисцидоз. М.: Медпрактика-М; 2014.
(check this in PDF content)
2
Каширская Н.Ю., Красовский С.А., Черняк А.В. и др. Динамика продолжительности жизни больных муковисцидозом, проживающих в Москве, и ее связь с получаемой терапией: ретроспективный анализ за 1993– 2013 гг. Вопросы современной педиатрии.2015; 14 (4): 503–508.
(check this in PDF content)
3
Красовский С.А., Черняк А.В., Каширская Н.Ю. и др. Муковисцидоз в России: создание национального регистра. Педиатрия. Журнал им. Г.Н.Сперанского. 2014; 93 (4): 44–55.
(check this in PDF content)
4
Boucher RC Evidence for airway surface dehydration as the initiating event in CF airway disease.J. Int. Med. 2007; 261:
(check this in PDF content)
5
16. 5. O’Sullivan B.P., Flume P. The clinical approach to lung disease in patients with cystic fibrosis.Semin. Respir. Crit. Care Med. 2009; 30 (5): 505–513.
(check this in PDF content)
6
Flume P.A., Robinson K.A., O’Sullivan B.P. et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir. Care.2009; 54: 522–537. * – www.proactiveinvestors.com.au/companies/news/66199/pharmaxis-enchances-outlook-for-cystic-fibrosis-treatment Горинова Ю.В. и др.Ингаляционный маннитол – новый муколитический препарат для лечения муковисцидоза
(check this in PDF content)
7
Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis: A European consensus.J. Cyst. Fibrosis. 2005; 4: 7–26.
(check this in PDF content)
8
Shah P., Conway S., Scott S. et al. A case-controlled study with Dornase Alfa to evaluate impact on disease progression over a 4 year period.J. Respiration. 2001; 68: 160–164.
(check this in PDF content)
9
Симонова О.И., Горинова Ю.В. Сравнительные характеристики известных муколитиков в базисной терапии муковисцидоза у детей. Педиатрическая фармакология. 2014; 11 (6): 96–103.
(check this in PDF content)
10
Fushs H.J., Borowitz D.S., Christiansen D.H. et al. Effect of aerolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 1994; 331: 637–642.
(check this in PDF content)
11
Mall M., Grubb B.R., Harkema J.R. et al. Increased airway epithelial Na+absorption produces cystic fibrosislike lung disease in mice. Nat. Med. 2004; 10: 487–493.
(check this in PDF content)
12
Robinson M., Hemming A.L., Regnis J.A. et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997; 52: 900–903.
(check this in PDF content)
13
Donaldson S.H., Bennett W.D., Zeman K.L. et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 2006; 354: 241–250.
(check this in PDF content)
14
Elkins M.R., Robinson M., Rose B.R. et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.N. Engl. J. Med.2006; 354 (3): 229–240.
(check this in PDF content)
15
Wark P., McDonald V.M. Nebulised hypertonic saline for cystic fibrosis. Cochr. Database Syst. Rev. 2009; 2: CD001506.
(check this in PDF content)
16
Rosenfeld M., Davis S., Brumback L. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: Short-term tolerability, adherence and safety. Pediatr. Pulm. 2011; 46 (7): 666–671.
(check this in PDF content)
17
Amin R., Subbarao P., Jabar A. et al. Hypertonic saline improves the LCI in pediatric patients with CF with normal lung function. Thorax. 2010; 65 (5): 379–383.
(check this in PDF content)
18
Симонова О.И., Горинова Ю.В., Бакрадзе М.Д. Эффективность ингаляций гипертонического раствора у детей с бронхитами и бронхиолитами. Вопросы современной педиатрии. 2014; 13 (4): 33–39.
(check this in PDF content)
19
Turino G.M., Cantor J.O. Hyaluronan in respiratory injury and repair. Am. J. Respir. Crit. Care Med.2003; 167: 1169–1175.
(check this in PDF content)
20
Buonpensiero P., De Gregorio F., Sepe A. et al. Hyaluronic acid improves ‘‘pleasantness’’ and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv. Ther. 2010; 27: 870–878.
(check this in PDF content)
21
Heijerman H., Westerman E., Conway S. et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.J. Cyst. Fibros.2009; 8 (5): 295–315.
(check this in PDF content)
22
Ratjen F. Restoring airway surface liquid in cystic fibrosis. N. Engl. J. Med. 2006; 354: 291–293.
(check this in PDF content)
23
Hurt K., Bilton D. Inhaled mannitol for the treatment of cystic fibrosis.Exp. Rev. Respir. Med.2012; 6: 19–26.
(check this in PDF content)
24
Anderson S.D., Brannan J., Spring J. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol.Am. J. Respir. Crit. Care Med. 1997; 156: 758–765.
(check this in PDF content)
25
Daviskas E., Anderson S.D., Brannan J.D. et al. Inhalation of drypowder mannitol increases mucociliary clearance. Eur. Respir. J. 1997; 10: 2449–2454.
(check this in PDF content)
26
Pettit R.S., Johnson C.E. Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann. Pharmacother.2011; 45: 49–59.
(check this in PDF content)
27
Bilton D., Robinson P., Cooper P. et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur. Respir. J. 2011; 38: 1071–1080.
(check this in PDF content)
28
Aitken M.L., Bellon G., De Boeck K. et al. Long-term inhaled dry powder mannitol in cystic fibrosis: in international randomized study.Am. J. Respir. Crit. Care Med. 2012: 185; 645–652.
(check this in PDF content)
29
Bilton D., Bellon G., Charlton B. Pooled analysis of two large randomized phase III inhaled mannitol studies in cystic fibrosis.J. Cystic. Fibros.2013: 12; 367–376.
(check this in PDF content)
30
Button B.M., Finlayson F., Borg B. Clinical impact of inhaled mannitol in an adult cystic fibrosis population. J. Cyst. Fibros.2013; 1: S98. Поступила 14.11.16
(check this in PDF content)